<DOC>
	<DOC>NCT02828397</DOC>
	<brief_summary>Primary Objective: Determine blood concentrations of two formulations of REGN2222 Secondary Objective: Assess safety and tolerability of REGN2222</brief_summary>
	<brief_title>Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Key 1. Healthy man or woman aged 18 to 60 years 2. Body weight between 50.0 kg and 95.0 kg, inclusive 3. Willing and able to comply with clinic visits and studyrelated procedures 4. Provide signed informed consent Key 1. Hemoglobin not within normal limits 2. Positive drug and alcohol screen test results at screening visits 1 and 2 3. Participation in any clinical research study that evaluated another investigational drug or therapy within 30 days or at least 5 halflives, whichever is longer, of the investigational drug, prior to the screening visit 4. Pregnant or breastfeeding women, and women of childbearing potential 5. Sexually active men who are unwilling to practice adequate contraception during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>